natgillin/translations-raw huggingface dataset:
A method of treating a condition selected from sleep disorders, stress, anxiety, major depression, and depression disorders in a subject in need thereof, comprising administration of an effective amount of the agomelatine hydrochloride hydrate according to claim 1 . 
Uporaba agomelatina hidroklorid hidrata prema zahtjevu 1 ili 2, naznačena time, da je namijenjena za liječenje poremećaja melatonergičkog sustava, poremećaja spavanja, stresa, anksioznosti, sezonskih depresija, velike depresije, kardiovaskularnih bolesti, bolesti probavnog sustava, nesanice i umora uslijed promjene vremenske zone (jet lag), shizofrenije, fobije ili depresivnih poremećaja.
wherein all variables are defined as in claim 1; 
(Ib-2) pri čemu su sve varijable kako je definirano u zahtjevu 1;
The system of claim 8, wherein the at least one of the at least two pump segments comprises a first pump segment and wherein the at least one other pump segment comprises a second pump segment and wherein respective peaks of the pulses provided through the first pump segment and the second pump segment are approximately 180 degrees out of phase. 
Sustav prema zahtjevu 6, naznačen time, da barem jedan od najmanje dva segmenta (103) sisaljke sadrži prvi segment (1034) sisaljke 1 gdje barem jedan od sljedećeg segmenta sisaljke sadrži drugi segment (103b) sisaljke i pri čemu su odgovarajuće vršne vrijednosti pulseva (601a, 601b) dobivenih kroz prvi segment sisaljke i drugi segment sisaljke otprilike 180 stupnjeva izvan faze.
1,3,5(10)-estratrien-3, 15a, 16a, 17B-tetrol (Estetrol) for use in the treatment of brain injury in hippocampus region. 
,3,5(10)-estratrien-3,15a,16a,17B-tetrol (Estetrol) naznačen time da se koristi za upotrebu u liječenju ozljeda mozga u području hipokampusa.
In a preferred embodiment, the antibody, fragment, variant, fusion or derivative comprises a variable light chain (VL) in which CDR3 comprises or consists of the amino acid sequence: 
X3je Gili R pri čemu protutijelo ili fragment sadrži varijabilni laki lanac (VL) u kojem CDR3 sadrži ili se sastoji od sekvence amino kiselina: CAAWDX,X5X;X7GLXg
optionally seeding with Form 1; 
izbornom zasijavanju Oblikom 1;
A compound of Formula VId: 
time formirajući spoj Formule IIb gdje je R16 OH;
An inhaler according to claim 1, wherein the air inlet of the manifold defines a sole point for entry for external air into the inhaler. 
Inhalator u skladu s patentnim zahtjevom 1 ili 2, pri čemu ulaz zraka (125) cjevovoda određuje jedinu točku za ulaz za vanjski zrak u inhalator.
The antibody, or fragment thereof, of any one of Claims 1-3, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10. 
Protutijelo koje se specifično veže na ljudski CSF-1R (SEQ ID NO. 16), naznačeno time što sadrži teški lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:9 i laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:10.
a C3-8 cycloalkenyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group B, 
C4.1a aril-Crsalkil skupina (gdje Csa aril je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B) ili
A treated seed comprising a compound of any of Claims 1 to 9 in an amount of from about 0.0001 to 1 % by weight of the seed before treatment. 
Tretirano sjeme koje sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9 u količini od oko 0.0001 do 1 težinskih % sjemena prije tretmana.
Lock according to one of the preceding claims, wherein the passage, viewed from the top down, is configured to become wider. 
Zatvarač (1) u skladu s jednim od prethodnih patentnih zahtjeva, kod kojeg je prolaz (19), gledano odozgo prema dolje, konfiguriran tako da postaje širi.
An anti-CD20 antibody formulation comprising 20 - 300 mg/ml of atumumab, 10 to 100 mM sodium acetate, 25 to 100 mM sodium chloride, 0.5 to 5% arginine free base, 0.02 to 0.2 mM EDTA, 0.01 to 0.2% polysorbate 80 and adjusted to pH 5.0 to 7.0, for use in the treatment of an immune disease and/or autoimmune disease. 
Formulacija protutijela anti-CD20, naznačena time, da obuhvaća od 20 do 300 mg/mL ofatumumaba, pri čemu formulacija nadalje obuhvaća od 10 do 100 mM natrijevog acetata, od 25 do 100 mM natrijevog klorida, od 0,5 do 5% slobodne baze arginina, od 0,02 do 0,2 mM EDTA, od 0,01 do 0,2% polisorbata 80, i podešava se na pH-vrijednost od 5,0 do 7,0. [image]
The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-10, wherein the light chain has an amino acid sequence selected from the group consisting of SEQ ID NOs: 34-37, 202-220, and 221. 
Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 8, naznačen(o) time, da slabi lanac ima jednu amino kiselinsku sekvencu od SEQ ID NO: 36.
transplanting one or more human cells into the mouse; administering a drug candidate to said mouse; and monitoring the human cells in the mouse to determine the therapeutic efficacy of the drug candidate. 
(b) primjeni kandidatnog lijeka na navedenom glodavcu; i (c) praćenju ljudskih stanica u glodavcu kako bi se odredilo terapijsku djelotvornost kandidatnog lijeka.
is selected from hydrogen, methyl, F or Cl; 
R* je izabran od vodika, metil, F ili Cl;
of the tumor-associated antigen, in a biological sample isolated from a patient, with said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
A pharmaceutical composition according to claim 1 or 2, wherein the renin inhibitor is a δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative, or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak u skladu sa zahtjevom 16, naznačen time, da inhibitor renina je derivat amida δ-amino-Y-hidroksi-w-aril-alkanoične kiseline ili je njegova farmaceutski prihvatljiva sol.
The compound or a salt thereof according to any one of claims 1 to 5, wherein R5 is a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C2-6 alkenyl group, an optionally substituted C2-6 alkynyl group, a hydroxyl-protecting group or a thiol-protecting group, wherein the substituents for the C1-6 alkyl group, the C2-6 alkenyl group and the C2-6 alkynyl group of R5, the hydroxyl-protecting group and the thiol-protecting group are defined as Claim 1. 
Spoj ili njegova sol u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da je R? vodikov atom, po izboru supstituirana Cig alkil skupina, po izboru supstituirana C,4 alkenil skupina, po izboru supstituirana C2.4 alkinil skupina, hidroksilna zaštitna skupina ili tiol zaštitna skupina, pri čemu su supstituenti za C,.g alkil skupinu, C24 alkenilnu skupinu i C24 alkinil skupinu od R?, hidroksil-zaštitna skupina i tiol-zaštitna skupina kao stoje definirano u patentnom zahtjevu 1.
The peptide analog of claim 13, wherein the peptide analog further includes one or more gamma-glutamic acid residues covalently linked to the C-terminus. 
Analog peptida prema zahtjevu 13, naznačen time, da analog peptida nadalje obuhvaća jedan ili više taloga gama-glutaminske kiseline kovalentno vezanih na C-završetak.
A process according to claim 1, wherein said filling medium is at least one of immiscible with and not dissolved by a cooling lubricant used for said mechanical machining. 
Postupak prema zahtjevu 1, naznačen time, da se upotrebljava punilo koje se ne miješa i/ili koje se ne otapa u sredstvu za hlađenje upotrijebljenom za mehaničku strojnu obradu, i upotrijebljeno punilo ponajprije nije topivo u vodi.
The antibody of any one of the preceding claims, which is a humanized antibody or a human antibody. The antibody of any one of the preceding claims, which is a monoclonal antibody. 
Monoklonsko protutijelo u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da je humanizirano protutijelo ili ljudsko protutijelo.
The process according to claim 5 wherein the resinous extract obtained in b. and the extract depleted of sennosides obtained in d. are admixed. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time, da se smolasti ekstrakt dobiven u fazi b. i ekstrakt osiromašen sa senozidom koji je dobiven u fazi d. pomiješaju.
A process for the preparation of Compound 31, comprising contacting Compound 30 with a mixture of nitric acid and sulfuric acid in the presence of dichloromethane 
HR P20171901 T1 7. = Postupak za dobivanje spoja 31, naznačen time da sadrži dovođenje u kontakt spoja 30 sa smjesom dušične kiseline i sumporne kiseline u prisutnosti diklorometana.
In some embodiments the feeding steps respectively comprise continuously feeding the predispersion and the remaining portion of the viscous material into the first container; and the method further comprises intermittently or continuously removing a reaction product thereof from the first container. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da koraci dodavanja redom sadrže kontinuirano dovođenje predisperziju i preostali dio viskoznog materijala u prvi spremnik; a navedeni postupak dodatno obuhvaća povremeno ili kontinuirano uklanjanje njegovog reakcijskog proizvoda iz prvog spremnika.
R is selected from the group consisting of hydrogen; C1-8 alkyl; C3-6cycloalkyl; (C3-6)cycloalkyl(C1-3)alkyl; phenyl(C1-3)alkyl; and phenyl(C1-3)alkyl substituted with 1-3 members of the group consisting of C1-8 alkyl, trifluoromethyl, nitro, dialkylamino and cyano; 
R je odabran iz skupine koja se sastoji od vodika; C,.g alkila; C2g cikloalkila; (Cz.g)cikloalkil(C;.2) alkila; feni(C.. aalkila; i feniKC,s)alkila supstituiranog s 1-3 člana skupine koja se sastoji od C,.s alkila, trifluorometila, nitro, dialkilamino i cijano;
Use of a compound selected from: for preparing copanlisib (10): or copanlisib dihydrochloride (11): 
Uporaba spoja: za pripravu kopanlisiba (10): ili kopanlisib dihidroklorida (11): ili kopanlisib dihidroklorid hidrata I, ili kopanlisib dihidroklorid hidrata II.
The carrier of any of claims 1 to 6, wherein the molecular sieve lies within a thermoplastic container. 
Nosač prema bilo kojem zahtjevu 1 do 7, gdje molekularno sito leži unutar termoplastičnog spremnika.
Process for the preparation of Oxytocin analogues of the formula I wherein 
Postupak pripreme oksitocinskih analoga formule I, naznačen time, da
The method of claim 17, said silane comprising a silane selected from the group consisting of gamma-aminopropyltriethoxysilane, N-(2-aminoethyl)-3-aminopropyltrimethoxysilane, phenol trimethoxysilane, gamma-glycidoxypropyltrimethoxysilane, and combinations thereof. 
Uporaba prema bilo kojem od zahtjeva 6 do 10, naznačena time da pripravak pored silana sadrži, poželjno, gamaaminopropiltrietoksisilan, - N-(2-aminoetil)-3-aminopropiltrimetoksisilan, fenol
An article of manufacture comprising a composition effective to treat an HCV infection or to inhibit the NS5B polymerase of HCV and packaging material comprising a label which indicates that the composition can be used to treat infection by the hepatitis C virus, wherein said composition comprises a compound according to claim 1 or a pharmaceutically acceptable salt or ester thereof. A compound selected from 
Predmet proizvodnje, naznačen time, da obuhvaća sastav učinkovit za liječenje HCV-infekcije ili za inhibiciju NS5B-polimeraze od HCV-a te pakirni materijal koji sadrži etiketu koja naznačava da se sastav može upotrebljavati za liječenje infekcije od virusnog hepatitisa C, pri čemu spomenuti sastav obuhvaća spoj prema jednom ili više od zahtjeva 1 do 11 ili njegovu farmaceutski prihvatljivu sol ili njegov ester.
a combination thereof, wherein the substance binds to activated HGF B chain and inhibits specific binding of said activated HGF B chain to c-met, for treating a pathological condition associated with activation of c-met in a subject, wherein the pathological condition is a cancer, tumor, cell proliferative disorder, immune disorder or angiogenesis-related disorder. 
njihova kombinacija, pri čemu se tvar veže na aktivirani HGF B lanac i inhibira specifično vezanje spomenutog aktiviranog HGF B lanca na c-met, za liječenje patološkog stanja povezanog s aktivacijom c-met u pojedincu, pri čemu patološko stanje je rak, tumor, poremećaj proliferacije stanica, imunosni poremećaj ili poremećaj povezan s angiogenezom.
The antibody or fragment thereof according to clause 1, which is capable of blocking PGLYRP1-induced activation of TREM-1. The antibody or fragment thereof according to any one of clauses 1-2, which competes with mAb 0170 for binding to SEQ ID NO: 1 (human TREM-1). 
Antitijelo ili njegov fragment u skladu sa patentnim zahtjevom 1, koje se natječe sa mAb 0170 za vezivanje za SEQ ID NO:1 koja predstavlja aminokiselinsku sekvencu humanog TREM-I, gdje mAb 0170 sadrži teški lanac koji sadrži sekvencu SEQ ID NO: 4, i laki lanac koji sadrži sekvencu SEQ ID NO: 5.
The combination of claim 1, wherein the IG in the composition is formulated for subcutaneous infusion by gravity, pump infusion or injection in an amount that is 20 to 30 grams. 
Kombinacija prema zahtjevu 1, naznačena time da je IG u pripravku formuliran za supkutanu infuziju gravitacijom, pumpnom infuzijom ili ubrizgavanjem u količini koja je 20 do 30 grama.
The diabody molecule of claim 5, wherein the second polypeptide chain additionally comprises: 
Molekula diatijela prema zahtjevu 5, naznačena time što drugi polipeptidni lanac dodatno sadrži:
(m-2) adding water and an alcohol selected from methanol, ethanol, isopropanol and n-propanol and allowing crystallisation of the compound of the Formula X to occur, collecting the compound of the Formula X and washing the compound of the Formula X with a mixture of water and the alcohol selected from methanol, ethanol, isopropanol and n-propanol, followed by a solvent selected from ethyl acetate, butyl acetate and acetonitrile at a temperature in the range of from 25 to 55°C; 
C; ili (m-2) dodavanja vode i alkohola izabranog od metanola, etanola, izopropanola i n-propanola i dozvoljavanja kristalizacije spoja formule X, i sakupljanja spoja formulom X i pranja spoja sa formulom X sa mješavinom vode i alkohola izabranog od metanola, etanola, izopropanola i n-propanola, a nakon toga sa otapalom izabranim između 20
The pharmaceutical composition of any one of the above (30.)-(58.) for use in the treatment of a cardiovascular disease. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3- 7 za primjenu u liječenju kardiovaskularne bolesti.
An antigen-binding fragment of the antibody can be, for example, a single chain Fv fragment (scFv), a F(ab′) fragment, a F(ab) fragment, and an F(ab′)2 fragment. 
Antitijelo ili njegov fragment u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je odabrani iz skupine koja se sastoji od jednog Fv fragmenta pojedinačnog lanca (scFv), jednog F(ab') fragmenta, jednog F(ab) fragmenta 1 jednog F(ab')2 fragmenta.
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage. 
pri čemu se ‘gap’ segment nalazi između 5’ ‘wing’ segmenta i 3’ ‘wing’ segmenta, pri čemu se svaki nukleozid od svakog ‘wing’ segmenta sastoji od 2’-O-metoksietil šećera; pri čemu je svaki citozin modificiranog oligonukleotida 5-metilcitozin, te pri čemu je svaka internukleozidna veza modificiranog oligonukleotida fosforotioatna veza.
The composition or preparation is a solution of methylnaltrexone or a salt thereof wherein the pH is below 4.25. 
Farmaceutski pripravak koji sadrži otopinu metilnaltreksona ili njegove soli, naznačen time da pripravak ima pH ispod 4,25.
Use of a compound as claimed in paragraphs 1 to 9 for the manufacture of a medicament for the treatment or prevention of a central nervous system disorder, inflammation, pain, or neovascularization. 
Upotreba spoja prema zahtjevu 1 ili 2 u proizvodnji lijeka za liječenje ili sprječavanje poremećaja središnjeg živčanog sustava, upale, boli ili neovaskularizacije.
At this point, the user may bring in the fenders, and may turn the system off, using the deactivation procedure described above. 
U ovom trenutku, korisnik može podići bokobrane, te isključiti sustav, koristeći postupak deaktiviranja kako je gore opisano.
A method for reducing the number of episodes of death caused by acute myocardial infarction in patients as compared to a control group treated with L-carnitine in saline comprising intravenously administering L-carnitine or one of its pharmaceutically acceptable salts within 6 hours of the onset of symptoms of acute myocardial infarction to patients in need thereof, at an initial dose of 9 grams a day, in combination with 1000-1500 ml of a 5% glucose solution for 5 days, followed by orally administering the L-carnitine or one of its pharmaceutically acceptable salts at a dose of 4 grams a day, whereby said number of episodes of death caused by acute myocardial infarction are reduced compared to said control group. 
HR P20120178 T1 PATENTNI ZAHTJEVI m Kombinirana upotreba L-kamnitina, ili jedne od njegovih farmaceutski prihvatljivih soli, 1 glukoze u pripravi medikamenta, korisna za smanjivanje broja dana koje infarktni pacijenti provedu na intenzivnoj njezi u bolnici i for smanjivanje broja epizodi postinfarktnog zatajenja srca, gdje se L-karnitin primijenjuje intravenski, unutar 6 sati od početka simptoma akutnog infarkta miokarda, u početnoj dozi od 9 g dnevno, naznačena time što je se primijenjuje u kombinaciji s 1000-1500 ml 5%-tne glukozne otopine u trajanju od 5 dana, nakon čega se liječenje L-karnitinom nastavlja u dozi od 4 g dnevno, oralnom primjenom.
A process for manufacturing the compound of formula I-3 or a salt thereof, said process comprising: 
Postupak za proizvodnju spoja sljedeće formule I3:
In one embodiment, a subject has a circulating basophil count of at least 5 cells/microL, at least 10 cells/microL, at least 15 cells/microL, at least 20 cells/microL, at least 30 cells/microL, at least 50 cells/microL, at least 60 cells/microL, at least 100 cells/microL prior to the administration of the one or more doses of one or more IL-5R binding molecules. 
Protutijelo za uporabu prema bilo kojem od zahtjeva 1-6, naznačeno time da navedeni subjekt prije davanja ima apsolutni broj bazofila od barem 5, barem 10, barem 15, najmanje 20, barem 30, barem 50, barem 60, ili barem 100 bazofila/mm'.
Preparation of pellets containing venlafaxine hydrochloride kg of venlafaxine hydrochloride, 7.26 kg of microcrystalline cellulose, 0.13 kg of colloidal silicon dioxide, 5.97 kg of sodium chloride and 0.32 kg of potassium chloride were homogenized in a high-shear granulator of Diosna V-100 type. 
Priređivanje granula koje sadrže venlafaksin hidroklorid 11,0 kg venlafaksin hidroklorida, 7,26 kg mikrokristalne celuloze, 0,13 kg koloidnog silicijeva dioksida, 5,97 kg natrijeva klorida i 0,32 kg kalijeva klorida je homogenizirano u 'high-shear' granulatoru tipa Diosna V-100.
The method according to claim 1 or 12, wherein the number of oil droplets having a size of >1.2 um in the second emulsion is 5×1010/ml or less. 
Postupak prema bilo kojem od zahtjeva 6 do 17, naznačen time da je broj kapljica ulja veličine > 1.2 um u drugoj emulziji 5 x 10/! /mlili manji.
A capsule according to claim 7 or any one of claims 24 - 33, wherein a ridge of the plurality of ridges (28.i) has a maximum width (WR) of less than 0.3 mm, preferably less than 0.21 mm, more preferably less than 0.15 mm. 
Sistem prema bilo kojem od patentnih zahtjeva 2-13, naznačen time da ispust (28.i) koji se sastoji od mnoštva ispusta (28.i) ima maksimalnu širinu manju od 0.3 mm, poželjnije manju od 0.21 mm, još poželjnije manju od 0.15 mm.
The reaction mixture is typically cooled at a rate of about 1°C to about 6°C per hour and preferably, at a rate of about 2°C to about 4°C per hour. 
Reakcijska smjesa se obično hladi brzinom 1C do 6"C na sat, i poželjno, 2Cdo 4*C na sat.
The method according to claim 1, wherein R14 represents an unsubstituted, or a mono- or di-substituted phenyl group. 
Derivati tiazolidin-4-ona prema zahtjevima 4 i 5, naznačeni time, da R'* predstavlja nesupstituiranu, ili mono- ili di-supstituiranu fenilnu skupinu.
The compound, pharmaceutically acceptable salt thereof or composition of Claim 8, for administration with a second therapeutic agent selected from a second HIV protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, a nucleoside/nucleotide reverse transcriptase inhibitor, a viral entry inhibitor, an integrase inhibitor, an immune based antiretroviral agent, a viral maturation inhibitor, a cellular inhibitor, and combinations of two or more of the above. 
HIV infekcije kod pacijenta. Spoj ili kompozicija prema zahtjevu 15 za davanje s drugim terapeutskim sredstvom koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozidnog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaska virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili kombinacija dva ili više gore navedenih.
has a rearrangement in the gene encoding factor VIII; 
(b) ima preuređivanje u genu koji kodira faktor VIII;
The molecule for use of claim 3, wherein the immunoglobulin is an immunoglobulin constant region or portion thereof. 
Molekula za uporabu iz patentnog zahtjeva 3, pri čemu je imunoglobulin konstantna regija imunoglobulina ili njen dio.
An object according to any one or more of claims 1-3, characterised in that component B of the paint composition is an aromatic isocyanate prepolymer and/or an aliphatic isocyanate prepolymer. 
Objekt sukladno bilo kojem ili više Zahtjeva 1 - 3, naznačen time što je komponenta B sastava boje aromatični prepolimer izocijanata i/ili aifatski prepolimer izocijanata.
A further object of the present invention is to provide a sheet for packaging food that is capable of ensuring better preservation over time of the organoleptic characteristics and of the freshness and appearance of the packaged food. 
Daljnji cilj predloženog izuma je osigurati foliju za pakiranje hrane koja može osigurati tijekom vremena bolje održavanje organoleptičkih karakteristika, te svježine i izgleda upakirane hrane.
at least one sealing member (4, 9) to provide a seal to the pipe (2) received in said sleeve end (3, 10); 
- < najmanje jedan brtveni element (4) za uspostavljanje brtvenog spoja između naglavka (10) 1 cijevi (2); -
a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. A pharmaceutical combination for use according to claim 19, wherein the first active is 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide or a pharmaceutically acceptable salt thereof. 
prvi djelatni sastojak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do 12, i drugi djelatni sastojak odabran od sljedećih: osmotska sredstva, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminska sredstva, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvi i drugi djelatni sastojci mogu biti u istom ili u drugačijem farmaceutskom sastavu.
represents any structure of the following formula group [4']: 
Z' predstavlja bilo koja struktura prema slijedećoj skupini formula [4']: